[ad_1]
DUBLIN – (Business Wire) – Hepatitis
Drug Development Pipeline Review, 2018 "Report has been added
at the offer of ResearchAndMarkets.com .
This report provides an overview of the hepatitis pipeline landscape
infections. It provides comprehensive information on therapeutics
in development and key players in therapeutic development
for hepatitis A, hepatitis B, hepatitis D and hepatitis E, and features
dormant and discontinued products.
Hepatitis refers to inflammation of the liver and is most often
caused by viral infections. Hepatitis A and E are usually caused by
ingestion of contaminated food or water. The symptoms of hepatitis A
infection include fatigue, nausea and vomiting, loss of appetite, dark
urine, muscle pain and yellowing of the skin and eyes.
Risk factors include a weakened immune system and the use of
illicit drugs not injected. The symptoms of hepatitis E include yellowing
skin, dark urine, fever, fatigue, joint pain, nausea, loss of
appetite and pain in the abdomen.
Hepatitis B and hepatitis D usually occur as a result of
contact with infected body fluids. Transmission of hepatitis B can occur
through badual contact, injection of drugs or transfusion of
blood and blood products. The hepatitis B virus can cause acute illness
with symptoms that last for several weeks, including yellowing of the skin
and eyes, dark urine, extreme tiredness, nausea, vomiting and abdominal
pain.
Infection with hepatitis D virus occurs only in infected persons
hepatitis B because the hepatitis D virus can only reproduce in the presence
of hepatitis B. The co-infection of hepatitis B and hepatitis D is
badociated with greater severity of the disease than hepatitis B
alone.
Featured companies
- Abivax SA
- AiCuris GmbH & Co KG
- Aucta Pharmaceuticals LLC
- Beijing Kawin Technology Part-Holding Co Ltd
- Bukwang Pharm Co Ltd
- Cocrystal Pharma Inc
- CyTuVax BV
- DelSiTech Ltd
- Dicerna Pharmaceuticals Inc
- Dong-A Socio Holdings Co Ltd
- Together Therapeutics Corp
- GC Pharma
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Intellia Therapeutic Inc
- Ionis Pharmaceuticals Inc
- ISA Pharmaceuticals BV
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Johnson & Johnson
- Medicine Kainos Inc
- Kineta Inc
- LG Chem Ltd
- Microbiotix Inc.
- MultiCell Technologies Inc
- Oncolys BioPharma Inc.
- Pfenex Inc.
- Rodos BioTarget GmbH
- Samjin Pharm Co Ltd
- Sanofi Pasteur SA
- Spring Bank Pharmaceuticals Inc
- TCM Biotech International Company
- Theravectys SA
- VBI Vaccines Inc
- VLP Biotech Inc.
- and many others …
Main Topics
1 Table of Contents
2 Introduction
3 Therapeutic development
4 Therapeutic evaluation
5 companies involved in therapeutic development
6 dormant projects
7 Discontinued products
8 product development milestones
9 Appendix
For more information on this report, visit https://www.researchandmarkets.com/research/kk9fhh/2018_hepatitis?w=4
See the source version on businesswire.com: https://www.businesswire.com/news/home/20180706005139/en/
ResearchAndMarkets.com
Laura Wood, Senior Director
press @ researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
Call For Free In The US And Canada
1-800-526-8630
For GMT office hours, call + 353-1-416-8900
Topics: Drugs
Discovery Infectious
Drug Diseases Liver
and drugs for renal disorders
[ad_2]
Source link
